• Century Therapeutics published a medical research presentation outlining preclinical data for CNTY-813, an iPSC-derived islet cell therapy for type 1 diabetes.
• Program positioned as an off-the-shelf approach, pairing scalable bioreactor manufacturing with immune-evasive engineering intended to reduce rejection risk.
• Preclinical results showed glucose-responsive insulin secretion comparable to primary islets, rapid restoration of normoglycemia in diabetic mice, durability beyond 8 months.
• Safety readouts cited no tumorigenesis in more than 140 mice with more than 3 months of follow-up, no cyst formation through 8 weeks.
• Humanized mouse studies indicated preserved graft function under alloimmune pressure versus unedited islets, using C-peptide response and glucose tolerance testing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Century Therapeutics Inc published the original content used to generate this news brief on June 08, 2026, and is solely responsible for the information contained therein.